$DHAI
DIH HOLDING US, INC. Stock $dhai

$dhai Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-Q Financial Statement

#000149315223019137 Filed on May 25, 2023

Income Statement

Concept	2023 Q1	2022 Q1
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$1.552M	$797.4K
YoY Change	94.59%
Operating Profit	-$1.552M	-$797.4K
YoY Change	94.59%
Interest Expense	$1.190M	$3.637M
YoY Change	-67.27%
% of Operating Profit
Other Income/Expense, Net	$1.190M	$3.895M
YoY Change	-69.44%
Pretax Income	-$361.4K	$3.098M
YoY Change	-111.67%
Income Tax
% Of Pretax Income
Net Earnings	-$361.4K	$3.098M
YoY Change	-111.67%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.02	$122.4K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.830K	$593.8K
YoY Change	-98.34%
Cash & Equivalents	$9.828K	$593.8K
Short-Term Investments
Other Short-Term Assets	$254.6K	$503.6K
YoY Change	-49.44%
Inventory	$4.850M
Prepaid Expenses	$254.6K
Receivables	$5.998M
Other Receivables	$6.383M
Total Short-Term Assets	$264.4K	$1.097M
YoY Change	-75.9%
LONG-TERM ASSETS
Property, Plant & Equipment	$742.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$59.10M	$204.0M
YoY Change	-71.03%
Other Assets	$772.0K	$165.0K
YoY Change	367.82%
Total Long-Term Assets	$59.10M	$204.2M
YoY Change	-71.06%
TOTAL ASSETS
Total Short-Term Assets	$264.4K	$1.097M
Total Long-Term Assets	$59.10M	$204.2M
Total Assets	$59.36M	$205.3M
YoY Change	-71.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$345.9K	$212.0K
YoY Change	63.13%
Accrued Expenses	$1.427M	$103.9K
YoY Change	1273.4%
Deferred Revenue	$7.714M
YoY Change
Short-Term Debt	$225.0K	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.048M	$315.9K
YoY Change	548.17%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$7.738M	$9.214M
YoY Change	-16.02%
Total Long-Term Liabilities	$7.738M	$9.214M
YoY Change	-16.02%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.048M	$315.9K
Total Long-Term Liabilities	$7.738M	$9.214M
Total Liabilities	$9.786M	$9.530M
YoY Change	2.68%
SHAREHOLDERS EQUITY
Retained Earnings	-$9.522M
YoY Change
Common Stock	$2.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$9.521M	-$8.267M
YoY Change
Total Liabilities & Shareholders Equity	$59.36M	$205.3M
YoY Change	-71.08%

Cashflow Statement

Concept	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$361.4K	$3.098M
YoY Change	-111.67%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$136.3K	-$747.2K
YoY Change	-81.76%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$149.1M	-$204.0M
YoY Change	-173.06%
Cash From Investing Activities	$149.1M	-$204.0M
YoY Change	-173.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$149.3M
YoY Change
Debt Paid & Issued, Net		$242.8K
YoY Change
Cash From Financing Activities	-$149.1M	205.3M
YoY Change	-172.63%
NET CHANGE
Cash From Operating Activities	-$136.3K	-747.2K
Cash From Investing Activities	$149.1M	-204.0M
Cash From Financing Activities	-$149.1M	205.3M
Net Change In Cash	-$181.3K	528.4K
YoY Change	-134.31%
FREE CASH FLOW
Cash From Operating Activities	-$136.3K	-$747.2K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001883788
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q1	us-gaap	Investment Income Dividend InvestmentIncomeDividend		usd
CY2023Q1	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue		usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited		usd
CY2022Q1	ATAK	Investmentincomedividends Investmentincomedividends		usd
CY2023Q1	ATAK	Allocation Of Deferred Offering Costs For Warrant Liability AllocationOfDeferredOfferingCostsForWarrantLiability		usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023Q1	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments		usd
CY2022Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities		usd
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities		usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2023Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt		usd
CY2023Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts		usd
CY2022Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
CY2023Q1	ATAK	Initial Measurement Of Classa Ordinary Shares Subject To Possible Redemption InitialMeasurementOfClassaOrdinarySharesSubjectToPossibleRedemption		usd
CY2023Q1	ATAK	Initial Measurement Of Public Warrants And Private Placement Warrants InitialMeasurementOfPublicWarrantsAndPrivatePlacementWarrants		usd
CY2023Q1	ATAK	Deferred Underwriting Fee Payable DeferredUnderwritingFeePayable		usd
CY2023Q1	ATAK	Forfeiture Of Representative Shares ForfeitureOfRepresentativeShares		usd
CY2023Q1	ATAK	Stock Issued During Period Representative Shares Issued Value Class A StockIssuedDuringPeriodRepresentativeSharesIssuedValueClassA		usd
CY2023Q1	ATAK	Deferred Offering Costs Incurred Included In Accrued Offering Costs DeferredOfferingCostsIncurredIncludedInAccruedOfferingCosts		usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-41250
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	AURORA TECHNOLOGY ACQUISITION CORP.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1624542
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	4 Embarcadero Center
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1449
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Francisco
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94105
CY2023Q1	dei	City Area Code CityAreaCode	650
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	550-0458
CY2023Q1	dei	Security12b Title Security12bTitle	Class A Ordinary Share, par value $0.0001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	ATAK
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	true
CY2023Q1	us-gaap	Cash Cash	9828	usd
CY2022Q4	us-gaap	Cash Cash	191103	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	254597	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	284597	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	264425	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	475700	usd
CY2023Q1	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	59096654	usd
CY2022Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	206879903	usd
CY2023Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	59096654	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	206879903	usd
CY2023Q1	us-gaap	Assets Assets	59361079	usd
CY2022Q4	us-gaap	Assets Assets	207355603	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	345866	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	30132	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1426693	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	357026	usd
CY2023Q1	ATAK	Accrued Offering Costs AccruedOfferingCosts	50000	usd
CY2022Q4	ATAK	Accrued Offering Costs AccruedOfferingCosts	50000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2047559	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	437158	usd
CY2023Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	668000	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	589420	usd
CY2023Q1	ATAK	Deferred Underwriting Commissions Noncurrent DeferredUnderwritingCommissionsNoncurrent	7070000	usd
CY2022Q4	ATAK	Deferred Underwriting Commissions Noncurrent DeferredUnderwritingCommissionsNoncurrent	7070000	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	7738000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	7659420	usd
CY2023Q1	us-gaap	Liabilities Liabilities	9785559	usd
CY2022Q4	us-gaap	Liabilities Liabilities	8096578	usd
CY2023Q1	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.42
CY2022Q4	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.24
CY2023Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	59096654	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	206879903	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-9521669	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7621413	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-9521134	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-7620878	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	59361079	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	207355603	usd
CY2023Q1	ATAK	Formation And Operating Costs FormationAndOperatingCosts	1551676	usd
CY2022Q1	ATAK	Formation And Operating Costs FormationAndOperatingCosts	797398	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1551676	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-797398	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	78580	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3636595	usd
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	258440	usd
CY2023Q1	us-gaap	Investment Income Dividend InvestmentIncomeDividend	1268885	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1190305	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3895035	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-361371	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	3097637	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-7620878	usd
CY2023Q1	ATAK	Remeasurement Of Redemption Value RemeasurementOfRedemptionValue	-1538885	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-361371	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-9521134	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	15037	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	15037	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	15037	usd
CY2022Q1	ATAK	Remeasurement Of Redemption Value RemeasurementOfRedemptionValue	-30006587	usd
CY2022Q1	ATAK	Stock Issued During Period Representative Shares Issued Value StockIssuedDuringPeriodRepresentativeSharesIssuedValue	3030000	usd
CY2022Q1	ATAK	Rights Underlying The Units Value RightsUnderlyingTheUnitsValue	15596420	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	3097637	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	3097637	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-8267493	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-8267493	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-361371	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	3097637	usd
CY2023Q1	ATAK	Investmentincomedividends Investmentincomedividends	1268885	usd
CY2022Q1	ATAK	Allocation Of Deferred Offering Costs For Warrant Liability AllocationOfDeferredOfferingCostsForWarrantLiability	516747	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	78580	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3636595	usd
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	258440	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-30000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	668590	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1385401	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	202073	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-136275	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-747168	usd
CY2022Q1	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	204020000	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	270000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	149322133	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	149052133	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-204020000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	202000000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	6470000	usd
CY2022Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2525000	usd
CY2023Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	225000	usd
CY2022Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	242801	usd
CY2022Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	406631	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	149322133	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-149097133	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	205295568	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-181275	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	528400	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	191103	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	65373	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9828	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	593773	usd
CY2022Q1	ATAK	Initial Measurement Of Classa Ordinary Shares Subject To Possible Redemption InitialMeasurementOfClassaOrdinarySharesSubjectToPossibleRedemption	174013413	usd
CY2022Q1	ATAK	Initial Measurement Of Public Warrants And Private Placement Warrants InitialMeasurementOfPublicWarrantsAndPrivatePlacementWarrants	5780547	usd
CY2022Q1	ATAK	Deferred Underwriting Fee Payable DeferredUnderwritingFeePayable	7070000	usd
CY2023Q1	ATAK	Remeasurement Of Class A Ordinary Shares Subject To Possible Redemption RemeasurementOfClassAOrdinarySharesSubjectToPossibleRedemption	1538885	usd
CY2022Q1	ATAK	Remeasurement Of Class A Ordinary Shares Subject To Possible Redemption RemeasurementOfClassAOrdinarySharesSubjectToPossibleRedemption	30006587	usd
CY2022Q1	ATAK	Forfeiture Of Representative Shares ForfeitureOfRepresentativeShares	-70	usd
CY2022Q1	ATAK	Stock Issued During Period Representative Shares Issued Value Class A StockIssuedDuringPeriodRepresentativeSharesIssuedValueClassA	30	usd
CY2022Q1	ATAK	Deferred Offering Costs Incurred Included In Accrued Offering Costs DeferredOfferingCostsIncurredIncludedInAccruedOfferingCosts	103884	usd
CY2022Q1	ATAK	Overallotment Option Liability OverallotmentOptionLiability	258440	usd
CY2022Q1	ATAK	Stock Issued During Period Representative Shares Issued Value StockIssuedDuringPeriodRepresentativeSharesIssuedValue	3030000	usd
CY2022Q1	ATAK	Rights Underlying The Units Value RightsUnderlyingTheUnitsValue	15596420	usd
CY2022Q1	us-gaap	Cash Cash	1468333	usd
CY2023Q1	us-gaap	Deposits Deposits	270000	usd
CY2023Q1	ATAK	Percentage Of Fair Market Value Of Target Business To Asset Held In Trust Account PercentageOfFairMarketValueOfTargetBusinessToAssetHeldInTrustAccount	0.80	pure
CY2023Q1	us-gaap	Minimum Net Worth Required For Compliance MinimumNetWorthRequiredForCompliance	5000001	usd
CY2023Q1	ATAK	Business Combination Extension Of Business Combination Period BusinessCombinationExtensionOfBusinessCombinationPeriod	extends the period of time to consummate the initial Business Combination up to six times, each by an additional one month (for a total of up to 24 months from the date of the Initial Public Offering to complete the Business Combination)
CY2023Q1	ATAK	Number Of Days Within Which Public Shares Shall Be Redeemed NumberOfDaysWithinWhichPublicSharesShallBeRedeemed	P10D
CY2023Q1	us-gaap	Liquidation Basis Of Accounting Accrued Costs To Dispose Of Assets And Liabilities LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities	50000	usd
CY2023Q1	us-gaap	Cash Cash	9828	usd
CY2022Q4	us-gaap	Cash Cash	191103	usd
CY2023Q1	ATAK	Net Working Capital Surplus Deficit NetWorkingCapitalSurplusDeficit	1783134	usd
CY2022Q4	ATAK	Net Working Capital Surplus Deficit NetWorkingCapitalSurplusDeficit	38542	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_849_eus-gaap--UseOfEstimates_z0pprGy9rkx2" style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86C_zpMHMxszp8a">Use of Estimates</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the condensed financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information becomes available. Accordingly, the actual results could differ significantly from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023Q1	ATAK	Percentage Of Public Shares To Be Redeemed In Case Business Combination Is Not Consummated PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated	1	pure
CY2022Q1	ATAK	Overallotment Option Liability OverallotmentOptionLiability	258440	usd
CY2022Q1	ATAK	Stock Issued During Period Representative Shares Issued Value StockIssuedDuringPeriodRepresentativeSharesIssuedValue	3030000	usd
CY2022Q1	ATAK	Rights Underlying The Units Value RightsUnderlyingTheUnitsValue	15596420	usd
CY2023Q1	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	14529877	shares
CY2023Q1	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	149322133	usd
CY2023Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zbLqx4AnO6o8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86A_zjtbiJptjS2">Concentration of Credit Risk</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $<span id="xdx_902_eus-gaap--CashFDICInsuredAmount_iI_c20230331_zsrig3n3soK9" title="Federal depository insurance coverage">250,000</span>. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	26670000	shares
CY2023Q1	ATAK	Minimum Lock In Period For Transfer Assign Or Sell Warrants After Completion Of Ipo MinimumLockInPeriodForTransferAssignOrSellWarrantsAfterCompletionOfIpo	P30D
CY2023Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	668000	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	589420	usd

Files In Submission

Name	View Source	Status
0001493152-23-019137-index-headers.html	Edgar Link	pending
0001493152-23-019137-index.html	Edgar Link	pending
0001493152-23-019137.txt	Edgar Link	pending
0001493152-23-019137-xbrl.zip	Edgar Link	pending
atak-20230331.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
atak-20230331_lab.xml	Edgar Link	unprocessable
atak-20230331_cal.xml	Edgar Link	unprocessable
atak-20230331_pre.xml	Edgar Link	unprocessable
atak-20230331_def.xml	Edgar Link	unprocessable
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DHAI
DIH HOLDING US, INC. Stock $dhai

2023 Q1 Form 10-Q Financial Statement

#000149315223019137 Filed on May 25, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DHAI DIH HOLDING US, INC. Stock $dhai

2023 Q1 Form 10-Q Financial Statement

#000149315223019137 Filed on May 25, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DHAI
DIH HOLDING US, INC. Stock $dhai